

DISCOVERY RESEARCH PUBLICATIONS

1. van der Valk F, Hassing C, Visser M, Thakkar P, Mohanan A, Pathak K, Dutt C, Chauthaiwale V, Ackermans M, Nederveen A, Serlie M, Nieuwdorp M, Stroes E. The effect of a diiodothyronine mimetic on insulin sensitivity in male cardiometabolic patients: a double-blind randomized controlled trial. *PLoS One* 2014; **9**
2. Dutt C, Chauthaiwale V, Mohanan A, Chandra KP, Zambad SP, Gupta R, Parikh S. The Evolving Face of Heart Failure Associated with Elevated Cardio-Metabolic Risk Factors, Cardiomyopathies - From Basic Research to Clinical Management. In: Prof. Josef Veselka, ed. *In Tech*, 2012
3. Zambad S, Munshi S, Dubey A, Gupta R, Busiello RA, Lanni A, Goglia F, Gupta RC, Chauthaiwale V, Dutt C. TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats. *Diabetes Metab Syndr Obes* 2011; **4**: 5–16.
4. Cioffi F, Zambad S, Chhipa L, Senesa R, Busiello RA, Tuli D, Munshi S, Moreno M, Lombardie A, Gupta RC, Chauthaiwale V, Dutt C, Lange P, Silvestri E, Lanni A, Goglia F. TRC150094, a novel functional analog of iodothyronines, reduces adiposity by increasing energy expenditure and fatty acid oxidation in rats receiving a high-fat diet. *FASEB J* 2010; **24**:3451-61
5. Joshi D, Shiwalkar A, Cross M, Sharma S, Vachhani A, Dutt C. Continuous, non-invasive measurement of the haemodynamic response to submaximal exercise in patients with diabetes mellitus. Evidence of impaired cardiac reserve and peripheral vascular response; *Heart* 2010; **96**:36-41.
6. Chandra KP, Shiwalkar A, Kotecha J, Thakkar P, Srivastava A, Chauthaiwale V, Sharma SK, Cross MR, Dutt C. Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects; *Clin Drug Investig*. 2009; **29**:559-75.
7. Joshi D, Gupta R, Dubey A, Shiwalkar, A, Pathak P, Gupta RC, Chauthaiwale V, Dutt C. TRC4186, a Novel AGE-breaker, Improves Diabetic Cardiomyopathy and Nephropathy in Ob-ZSF1 Model of Type 2 Diabetes. *J Cardiovas Pharmacol* 2009; **54**:72-81
8. Pathak P, Gupta R, Chaudhari A, Shiwalkar A, Dubey A, Mandhare AB, Gupta RC, Joshi D, Chauthaiwale V. TRC4149 a novel advanced glycation end product breaker improves hemodynamic status in diabetic spontaneously hypertensive rats; *Eur J Med Res* 2008;**13**:388-98.
9. Gupta R, Chaudhary A, Shah B, Jadhav A, Zambad S, Gupta RC, Deshpande S, Chauthaiwale V, Dutt C. Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis. *Clin Exp Gastroenterol* 2014; **7**:13-23.
10. Jamadarkhana P, Chaudhary A, Chhipa L, Dubey A, Mohanan A, Gupta R, Deshpande S. Treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates ischemic acute kidney injury. *Am J Nephrol* 2012; **36**:208-18.

11. Zambad S, Tuli D, Mathur A, Ghalsasi S, Chaudhary A, Deshpande S, Gupta RC, Chauthaiwale V, Dutt C. TRC210258, a novel TGR5 agonist, reduces glycemc and dyslipidemic cardiovascular risk in animal models of diabetes. *Diabetes Metab Syndr Obes* 2014; **7**:1-14.
12. Mohanan A, Gupta R, Dubey A, Jagtap V, Mandhare A, Gupta RC, Chauthaiwale V, Dutt C. TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats. *Int J Hypertens* 2011; 2011
13. Mohanan A, Deshpande S, Jamadarkhana PG, Kumar P, Gupta RC, Chauthaiwale V, Dutt C. Delayed intervention in experimental stroke with TRC051384 - A small molecule HSP70 inducer. *Neuropharmacology* 2011; **60**:991-99.
14. Shinde P, Srivastava SK, Odedara R, Tuli D, Munshi S, Patel J, Zambad SP, Sonawane R, Gupta RC, Chauthaiwale V, Dutt C. Synthesis of spiro[chroman-2,4'-piperidin]-4-one derivatives as acetyl-CoA carboxylase inhibitors. *Bioorg Med Chem Lett* 2009;**19**:949-53.
15. Gupta RC, Chhipa L, Mandhare AB, Zambad SP, Chauthaiwale V, Nadkarni S, Dutt C. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor. *Bioorg Med Chem Lett* 2009; **19**:5021-25.
16. Gupta R, Mohanan A, Joshi D. Development and validation of a Rat Model for Examining the AT₁ and ET_A receptor-Blocking Activity of Dual AT₁ and ET_A receptor Blockers. *High Blood Press Cardiovasc Prev* 2009; **16**:39-45